Covered recipient · General Payments record
CARA B BALLARD
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$5,248.98
- Reported across 337 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $263.60 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Abbott Laboratories | $64.53 | 3 |
| PFIZER INC. | $52.61 | 3 |
| Sumitomo Pharma America, Inc. | $44.97 | 3 |
| GlaxoSmithKline, LLC. | $40.51 | 2 |
| Exact Sciences Corporation | $16.07 | 1 |
| Astellas Pharma US Inc | $15.79 | 1 |
| Lilly USA, LLC | $15.22 | 1 |
| Amgen Inc. | $13.90 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $24.23 | 03/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125073516 | CMS |
| Abbott Laboratories | $17.29 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125073518 | CMS |
| Abbott Laboratories | $23.01 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125073520 | CMS |
| Amgen Inc. | $13.90 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117196892 | CMS |
| Astellas Pharma US Inc | $15.79 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139333960 | CMS |
| Exact Sciences Corporation | $16.07 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114584327 | CMS |
| GlaxoSmithKline, LLC. | $24.99 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116246924 | CMS |
| GlaxoSmithKline, LLC. | $15.52 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115928706 | CMS |
| Lilly USA, LLC | $15.22 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136080630 | CMS |
| PFIZER INC. | $16.30 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131727837 | CMS |
| PFIZER INC. | $16.52 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131736662 | CMS |
| PFIZER INC. | $19.79 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131882476 | CMS |
| Sumitomo Pharma America, Inc. | $14.35 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148824156 | CMS |
| Sumitomo Pharma America, Inc. | $15.22 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148824158 | CMS |
| Sumitomo Pharma America, Inc. | $15.40 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148824160 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.